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a b s t r a c t
Background: Extramammary Paget disease (EMPD) is a rare condition that most commonly
affects the anogenital region in the elderly. It may be associated with an underlying invasive
carcinoma. Surgical excision is nowadays considered a standard treatment for extramam-
mary Paget’s disease, although this approach might not be suitable for all patients. Good
rates of local control and cosmetic outcome have been achieved by using high-dose-rate
(HDR) plesiotherapy in the treatment of skin tumors arising in different locations.
Material and methods: We present the results observed in a patient with EMPD treated by HDR
plesiotherapy with a custom-made mold up to a ﬁnal dose of 54Gy in 12 fractions of 450
cGy over 4 weeks.
Results: After a follow-up of 18 months, the patient is alive and without evidence of local
or distant relapse. Acute toxicity was acceptable and cosmetic result was considered as
excellent.Conclusion: This technique represents an attractive alternative for those patients who are
not candidates for surgical procedures because of unacceptable risk of disﬁgurements or
functional impairment, medical contraindications or patient preference.
© 2012 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
6. Background
aget’s disease (PD) is a rare type of intraepithelial adenocar-
inoma characterized by the presence of malignant Paget’s
ells lying within the epidermis of the skin, ﬁrst described
y Sir James Paget in 1874.1 Extramammary Paget’s disease
EMPD) expresses the occurrence of this entity in areas con-
aining apocrine glands such as the perianal region, vulva,
enis, scrotum, perineum and axilla, different from the breast
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nipple. The ﬁrst case of EMPD of the anogenital area was
reported by Crocker in 1888, and until 2010 almost 300 cases
have been published.2–4 The disease sites present as patchy
and well-circumscribed, erythematous eczema or erosions
together with itching, bleeding or burning.5 The prognosis
of simple EMPD is relatively favorable, reaching disease-free
and overall survival rates of above 70% at 5-year after cura-tary Hospital Ramon y Cajal, Cta. Colmenar Viejo, km 9.100, 28034
tive intention treatment. Wide surgical excision remains to
be the mainstream of therapy for vulvar Paget’s disease. How-
ever, local recurrence rates range from 12% to 58% of treated
. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Patient with two biopsied lesions of EMPD located Fig. 2 – Patient with the custom-made mold in place for
plesiotherapy during irradiation.in the right labium majus and on perianal skin.
women during the follow-up time, even after extensive local
resections.7–9 On theotherhand, radical surgerymorbidity can
be high, especially in the elderly. Radiotherapy has been used
only occasionally in this condition. Primary radiotherapy was
indicated in patients not suitable for surgery because of the
presence of irresectable tumors or co-morbidities precluding
radical surgery. Radiotherapy was also used occasionally in
the adjuvant setting following surgery or with palliative inten-
tion after recurrent disease.10,11 Recently, a curative role for
radiation therapy of EMPD has been proposed.12 We present
a case of vulvar and perianal Paget’s disease treated by HDR
brachytherapy with a custom made mold (plesiotherapy) with
curative intention.
2. Case report
A 79-year-old woman presented with a 2-year history of red-
ness and pruritus in the vulvar and perianal region. Clinical
examination revealed two well-circumscribed erythematous
plaques with some scattered whitish points on her right
labium majus and on perianal skin (Fig. 1). No enlarged
inguinal lymphnodeswere detected. Both areaswere biopsied
evidencing the presence of multiple Paget cells, forming irreg-
ular nests and scattering individually in a pagetoid pattern
in the epidermis, leading to the diagnoses of extramammary
Paget’s disease. Additional exams, including whole-body CT,
colonoscopy and gynecological examination did not reveal
an underlying malignancy. The patient was treated initially
by means of topical applications of imiquimod cream but in
the absence of response she was referred to the Radiation
Oncology Department. A treatment by means of HDR superﬁ-
cial brachytherapy (plesiotherapy) with a custom-made mold
encompassing both lesions with a security margin of at least
2 cm surrounding the visible disease was proposed and the
patient gave her consent to the treatment.Our technique of HDR plesiotherapy based upon custom-
made molds has been previously described.13 Brieﬂy, person-
alized molds consist of a ﬂexible pad of silicone rubber, 10mm
thick, with a customizable array of 6F plastic catheters embed-
ded separated by 1 cm that easily conforms to the shape of
surfaces. The number of plastic tubes and the separation
between them depended on the size of the area to be treated.
This area was deﬁned by the radiation oncologist being wide
enough to include an adequate margin of uninvolved skin of
at least 1 cm around the tumor or the surgical bed. A CT scan
carrying the mold with wire dummies inserted on the plastic
tubeswere obtained fromeachpatient at 1-mm-thin intervals.
The macroscopic tumor/surgical tumor bed with a margin
(planning target volume (PTV)), along with the surround-
ing organs at risk were contoured on these CT slices before
calculation. PTV dose distribution and additional treatment
parameters were calculated by using the 3D treatment plan-
ning software PLATO developed by Nucletron (Nucletron BV,
Veenendaal, the Netherlands). Treatment dose was prescribed
at 5mm depth from the surface of the mold. At the moment
of treatment, the personalized mold was applied to the tumor
lesion, placed in direct apposition to the skin of the involved
area, and kept in place by adhesive tape (Fig. 2). The mold was
then connected to a HDR equipment containing a 192-iridium
radioactive source (Microselectron Nucletron BV, Veenendal,
the Netherlands). Radiation treatment was administrated in
12 fractions of 450 cGy, 3 fractions a week over 4 weeks,
until a total dose of 54Gy (equivalent dose in 2-Gy fractions
(EQD2): 65.3Gy) was reached. Adverse effects of plesiother-
apy included acute grade 3 epithelitis on the treated areas
that resolved with topical measures 2 weeks after treatment
cessation. Postradiotherapy evaluation revealed a complete
disappearance of the Paget’s disease areas 3 months after dis-
charge. On the last follow-up at 18 months after plesiotherapy,
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o signs of tumor recurrence were noted with only two small
reas of hypopigmentation on the primary tumor bed (Fig. 3).
. Discussion
ccording to latest literature reviews, anogenital presenta-
ion represents 6.5% of all cases of PD. EMPD of the vulva
ccounts for less than 1% of all vulvar tumors.8 Unlike the
resentation in the nipple, where PD is almost invariably asso-
iated with the existence of a ductal adenocarcinoma, EMPD
f the anogenital region is less frequently associated with the
resence of an underlying malignancy with incidence ranging
rom 33% to 86%.6,7
Therapeutic management of EMPD is highly related to the
xistence of an underlying neoplasia and possible regional or
ystemic spread. Surgery is the treatment of choice for EMPD.
ide excision of the lesion with a margin of at least 3 cm
eyond the clinically affected area with subsequent recon-
truction of the tissue defect or abdominoperineal excision
as been recommended. Mohs micrographic surgery (MMS)
epresents an alternative to wide surgical resections, allow-
ng to spare more normal tissue than conventional surgery.
evertheless, local recurrence after different surgical excision
echniques is a common problem. In the vulvar region, vulvec-
omy has a 15% recurrence rate, Mohs micrographic surgery
as a 27% recurrence rate and a wide local excision has a 43%
ecurrence rate. Perianal EMPD recurs in 28% of patients after
MS and in 50% of patients after a wide local excision.6–9 Due
o the aggressiveness of radical operative procedures, surgi-
al excision cannot always be accomplished. Many of these
atients are not candidates for surgical procedures because
f medical contraindication, old age or risk of disﬁgurements
r functional impairment. Alternative treatments for EMPD,
ncluding systemic chemotherapy, chemo-radiotherapy, pho-
odynamic therapy and more recently topical therapies withafter 18 months (B) of treatment.
5-FU or imiquimod, have been shown to be effective in treating
anogenital EMPD.14–20
Radiotherapy could be considered a reliable alternative for
EMPD. Irradiation may be used as a deﬁnitive treatment in
patients refusing surgery or with poor conditions that con-
traindicate operation as well as an adjunctive therapy after
primary local excision.Although there areno randomized con-
trolled trials comparing surgical excision and radiotherapy
in the initial management of EMPD, results from published
reports suggest a possible beneﬁcial role for this modality of
treatment. However, despite the existing evidence, discrep-
ancies between studies on the total dose, dose per fraction
and the irradiation technique used (i.e. external photons or
electrons, interstitial brachytherapy, plesiotherapy), make it
difﬁcult to establish a deﬁnitive indication of radiotherapy in
EMPD.10–12,21 While most results come from reports limited
to one or at most two case-reports,22–26 some groups have
communicated results for larger series. Hata et al.12 reported
a clinical course of 22 patients with EMPD, with 10 patients
undergoing EBRT. With a follow-up ranging between 0.6 and
11 years, 13 out of the 22 patients suffered a disease recur-
rence. Only 3 patients developed a local relapse within the
radiation ﬁeld, whereas regional nodal or distant metastases
were seen in 10 patients, with an interval between 3 and
43 months after irradiation. Besa et al.27 treated 4 patients
with primary EMPD with EBRT alone or EBRT plus an inter-
stitial LDR brachytherapy implant to a total dose of 44–64Gy.
With a follow-up of 1.2–5 years, no cases of local in-ﬁeld
relapse were noted. Brown et al.28 published an extensive lit-
erature review on the use of radiotherapy in EMPD together
with 6 cases of their own. Exclusive irradiation was indicated
in patients with inoperable tumors and in those who had
severe medical contraindications. Postoperative radiother-
apy was indicated in the adjuvant setting following surgery
with close/positive margins or as salvage treatment in recur-
rent disease. The authors concluded that radiation doses of
50Gy (EQD2Gy) should be the minimum dose required for
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microscopic disease, whereas higher doses may be necessary
in the presence of gross tumor or an underlying invasive ade-
nocarcinoma. Brierley et al.29 reported results of radiotherapy
as primary treatment in 6 patients with EMPD. The total dose
ranged between 36 and 54Gy with a fraction size of 2–10Gy
using either photons or electrons. Local relapse occurred in
20% of patients. Luk et al.30 reported results observed in 6
patients with anogenital EMPD, 2 of them with an underlying
adenocarcinoma, treated by radiotherapy with doses ranging
from 42Gy to 70Gy. All 4 patients with EMPD alone remained
alive and disease-free at 2–14.8 years of follow-up. Only one
patient underwent salvage surgery for local relapse in the
outer margin of the radiotherapy ﬁeld. Finally, Burrows et al.21
and Moreno-Arias et al.31 treated 5 and 4 patients, respec-
tively, with superﬁcial orthovoltage to a total dose ranging
from 39.6Gy to 40.5Gy. During follow-up, no cases of local
relapse were observed.
Brachytherapy techniques have a long history in the treat-
ment of cancer and continue to play an important role
in cancer therapy. New developments in recent years have
opened up several new treatment possibilities enabling treat-
ments to be individualized.32,33 In this patient, we found that
themost suitable treatmentwas superﬁcial brachytherapy, the
so-called plesiotherapy, due to her performance status and
her refusal of surgical management. Comparatively, the out-
come of the treatment with radiotherapy was favorable for
anogenital EMPD. Acute tolerance was acceptable, with mod-
erate epithelitis resolving soon after completion of treatment.
To our knowledge, only two previous cases have been treated
by a custom-made mold HDR-plesiotherapy technique.30 Ple-
siotherapy involves the use of surface applicators in direct
contact with the tumor or surgical tumor bed. Our result is
consistent with those previously reported, suggesting sim-
ilar tumor control rates and clinical outcomes to external
radiotherapy. Plesiotherapy offers the additional advantage
of a better targeting of radiation and minimizing irradiation
of surrounding healthy tissue, as compared to other radio-
therapy techniques. In our opinion, plesiotherapy using an
afterloaded custom-mademold appears to be an ideal alterna-
tive for elderly patients with comorbilities, not candidates for
aggressive surgical management presenting with superﬁcial
tumors without inﬁltration in depth.
Prognosis of EMPD is closely related to the presence of inva-
sive disease. For in situ lesions, overall survival exceeds 75%,
but when EMPD becomes invasive, survival rates decrease
by 33% irrespective of the aggressiveness of local treatment,
since distant metastases are frequent even at the time of
diagnosis.34
4. Conclusion
Anogenital EMPD is a rare disease usually associated with
adnexal and visceral inﬁltrating tumors but sometimes may
present as a purely intraepithelial lesion prone to a deﬁni-
tive treatment. In spite of the fact that surgery is usually the
preferred treatment, radiotherapy offers a reasonable alterna-
tive in patients who are not candidates for surgery or refuse
it. Doses above 50Gy, and even higher, in the presence of an
underlying inﬁltrative neoplasia, are required to guarantee
1iotherapy 1 7 ( 2 0 1 2 ) 163–167
acceptable local control. HDR-plesiotherpay with custom-
made molds is a worth-considering technique that shows an
acceptable outcome with good tolerance and appears to be
an ideal alternative for elderly patients, not candidates for
aggressive surgical impairment.
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